Abstract
No public abstract is available from the verified source records.
Open public full textRights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureEmil Ramsø Kyvsgaard, Trine Lønbo Grantzau, Mia Dahl Sørensen, Michael Boe Møller, Lene Dissing Sjø, Morten Grauslund, Trine Trab, Linea Cecilie Melchior, Lærke Sloth Andersen, Caroline Riley, Carsten Utoft Niemann, Jacob Haaber, Thomas Stauffer Larsen, Michael Roost Clausen, Kirsten Grønbæk, Martin Hutchings, Simon Husby
Abstract
Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study
10.1200/jco.21.00931 · 2022
Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM-2
10.1182/blood-2022-158406 · 2022
Relapse is uncommon in patients with large B-cell lymphoma who are in complete remission at the end of fixed-course glofitamab treatment
10.1182/blood-2022-157554 · 2022
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
10.1016/s0140-6736(21)00889-8 · 2021
Glofitamab for relapsed or refractory diffuse large B-cell lymphoma
10.1056/nejmoa2206913 · 2022
Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial
10.1200/jco.22.01725 · 2023
Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial
10.1200/jco.20.03175 · 2021
CAR T-cell therapy for B-cell lymphoma
10.1016/j.currproblcancer.2021.100826 · 2022
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1038/s41591-020-1061-7 · 2020
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
10.1182/bloodadvances.2021005954 · 2022
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
10.1200/jco.2013.54.8800 · 2014
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
10.1182/blood.2023022348 · 2024
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy
10.1182/blood.2023021672 · 2024
Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2
10.1200/jco.2023.41.16_suppl.tps7592 · 2023
Characterization of JNJ-80948543, a novel CD79bxCD20xCD3 trispecific T-cell redirecting antibody for the treatment of B-cell non-Hodgkin lymphoma
10.1182/blood-2022-168739 · 2022
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
10.1182/blood.2022015956 · 2022
No additional external references are available.